Pancreatic-Health & Cancer-Surveillance Comprehensive Panel
- $1,597.32
- $435
- Save: 72.77%
The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.
Amylase
Also known as: CA 125 Tumor Marker, CA-125, Cancer Antigen 125, OC125, Ovarian Antigen
Ca 125
Also known as: CA 199, Carbohydrate Antigen 19-9
Ca 19-9
Also known as: CBC, CBC includes Differential and Platelets, CBC/PLT w/DIFF, Complete Blood Count (includes Differential and Platelets)
NOTE: Ulta Lab Tests provides CBC test results from Quest Diagnostics as they are reported. Often, different biomarker results are made available at different time intervals. When reporting the results, Ulta Lab Tests denotes those biomarkers not yet reported as 'pending' for every biomarker the test might report. Only biomarkers Quest Diagnostics observes are incorporated and represented in the final CBC test results provided by Ulta Lab Tests.
Absolute Band Neutrophils (Only Reported If Detected)
Absolute Basophils
Absolute Blasts (Only Reported If Detected)
Absolute Eosinophils
Absolute Lymphocytes
Absolute Metamyelocytes (Only Reported If Detected)
Absolute Monocytes
Absolute Myelocytes (Only Reported If Detected)
Absolute Neutrophils
Absolute Nucleated Rbc (Only Reported If Detected)
Absolute Promyelocytes (Only Reported If Detected)
Band Neutrophils (Only Reported If Detected)
Basophils
Blasts (Only Reported If Detected)
Eosinophils
Hematocrit
Hemoglobin
Lymphocytes
MCH
MCHC
MCV
Metamyelocytes (Only Reported If Detected)
Monocytes
MPV
Myelocytes (Only Reported If Detected)
Neutrophils
Nucleated Rbc (Only Reported If Detected)
Platelet Count
Promyelocytes (Only Reported If Detected)
RDW
Reactive Lymphocytes (Only Reported If Detected)
Red Blood Cell Count
White Blood Cell Count
Also known as: Carcinoembryonic Antigen
Cea
Also known as: Chem 12, Chemistry Panel, Chemistry Screen, CMP, Complete Metabolic Panel, Comprehensive Metabolic Panel CMP, SMA 12, SMA 20
Albumin
Albumin/Globulin Ratio
Alkaline Phosphatase
Alt
AST
Bilirubin, Total
Bun/Creatinine Ratio
Calcium
Carbon Dioxide
Chloride
Creatinine
Egfr African American
Egfr Non-Afr. American
GFR-AFRICAN AMERICAN
GFR-NON AFRICAN AMERICAN
Globulin
Glucose
Potassium
Protein, Total
Sodium
Urea Nitrogen (Bun)
Also known as: LPS
Lipase
Also known as: Lipid Panel with Ratios (fasting), Lipid Profile with Ratios (fasting), Lipids
Chol/HDLC Ratio
Cholesterol, Total
HDL Cholesterol
LDL-Cholesterol
LDL/HDL Ratio
Non HDL Cholesterol
Triglycerides
Also known as: Pancreatic Elastase1
Pancreatic Elastase-1
The Pancreatic-Health & Cancer-Surveillance Comprehensive Panel panel contains 9 tests with 67 biomarkers .
Overview of the Pancreatic-Health & Cancer-Surveillance Comprehensive Panel
The Pancreatic-Health & Cancer-Surveillance Comprehensive Panel is an integrated diagnostic and monitoring tool that evaluates both the functional health of the pancreas and the presence of possible malignancies associated with the pancreas and surrounding organs. It combines tumor markers, enzymatic function tests, metabolic indicators, and general systemic health markers to provide a holistic view of pancreatic function and cancer risk. This panel is particularly valuable for individuals with a personal or family history of pancreatic disorders, those experiencing unexplained gastrointestinal symptoms, or patients undergoing surveillance for pancreatic cancer recurrence or treatment response.
When and Why the Pancreatic-Health & Cancer-Surveillance Comprehensive Panel May Be Ordered
This panel may be ordered when a healthcare provider suspects pancreatic disease based on symptoms such as upper abdominal pain, jaundice, unexplained weight loss, persistent indigestion, changes in stool appearance, or new-onset diabetes. It is also used in individuals at increased risk for pancreatic cancer, such as those with chronic pancreatitis, hereditary cancer syndromes, or smoking history. Additionally, this panel may be ordered as part of ongoing monitoring in patients previously diagnosed with pancreatic disease or cancer to assess treatment effectiveness and check for signs of recurrence or complications such as exocrine insufficiency or metabolic imbalance.
What the Pancreatic-Health & Cancer-Surveillance Comprehensive Panel Checks For
This panel evaluates a broad range of biomarkers that assess enzyme production, inflammation, tumor marker levels, nutritional and metabolic status, and systemic health.
Amylase and lipase are digestive enzymes produced by the pancreas. Elevated levels of either may suggest acute pancreatitis or pancreatic duct obstruction, while decreased levels in the context of digestive symptoms can indicate chronic pancreatic insufficiency.
Pancreatic elastase-1 is a highly specific marker of exocrine pancreatic function and is used to assess enzyme output in the small intestine. Low levels point toward chronic pancreatic insufficiency, which may occur in conditions such as chronic pancreatitis, cystic fibrosis, or advanced pancreatic cancer.
CA 19-9 and CEA are tumor markers that help detect pancreatic and gastrointestinal malignancies. CA 19-9 is particularly associated with pancreatic adenocarcinoma, while CEA may be elevated in a broader range of cancers, including pancreatic, colorectal, and gastric tumors.
CA 125, though more commonly associated with ovarian cancer, may also be elevated in pancreatic and gastrointestinal cancers or in cases of peritoneal inflammation or ascites.
Complete Blood Count with Differential and Platelets evaluates red and white blood cells, hemoglobin levels, hematocrit, and platelets. It provides insight into anemia, infection, inflammation, and potential paraneoplastic effects.
Comprehensive Metabolic Panel (CMP) assesses liver and kidney function, blood glucose, electrolyte balance, and protein levels. This information is critical for evaluating systemic involvement, metabolic stress, and complications related to pancreatic disorders.
Lipid Panel with Ratios measures cholesterol and triglyceride levels and evaluates cardiovascular risk. Abnormal lipid levels can be associated with pancreatitis, metabolic syndrome, or diabetes, which often coexists with pancreatic dysfunction.
Conditions and Diseases the Pancreatic-Health & Cancer-Surveillance Comprehensive Panel Can Detect
This panel is designed to identify and monitor a variety of pancreatic and systemic conditions, including acute pancreatitis, chronic pancreatitis, pancreatic cancer, pancreatic exocrine insufficiency, gastrointestinal malignancies, and metabolic disorders related to pancreatic function.
Acute Pancreatitis
Acute pancreatitis is a sudden inflammation of the pancreas, often caused by gallstones or alcohol use. It presents with intense abdominal pain, nausea, and elevated serum amylase and lipase. The panel helps confirm the diagnosis and monitor severity and systemic impact through enzyme levels and the CMP.
Chronic Pancreatitis
Chronic pancreatitis involves long-term inflammation and irreversible damage to pancreatic tissue, resulting in decreased digestive enzyme production. Over time, this may lead to malabsorption, weight loss, and diabetes. Pancreatic elastase-1 is a key marker to detect exocrine insufficiency, while chronic inflammation may alter CBC and CMP values.
Pancreatic Cancer
Pancreatic cancer, especially ductal adenocarcinoma, is a highly lethal disease with often late presentation. CA 19-9 is the most commonly used tumor marker to detect and monitor pancreatic cancer. CEA and CA 125 may provide additional diagnostic or prognostic information. The panel also evaluates systemic health indicators and possible liver involvement through the CMP and CBC.
Pancreatic Exocrine Insufficiency
This condition occurs when the pancreas no longer produces sufficient digestive enzymes, often due to chronic pancreatitis or cancer. Pancreatic elastase-1 is a sensitive marker of this deficiency. It can be used to initiate enzyme replacement therapy and monitor treatment effectiveness.
Gastrointestinal Malignancies
CEA and CA 125 may be elevated in other gastrointestinal cancers such as colorectal or gastric cancer. Combined with CA 19-9, this panel aids in broader cancer surveillance, especially in patients with nonspecific abdominal symptoms or known malignancies.
Metabolic Disorders
The CMP and lipid panel provide important data on glucose control, liver function, and lipid metabolism. Pancreatic dysfunction can contribute to metabolic syndrome, diabetes, and cardiovascular risk, all of which are assessed through this panel.
How a Healthcare Professional Uses the Pancreatic-Health & Cancer-Surveillance Comprehensive Panel Results
Acute Pancreatitis
Elevated amylase and lipase confirm the diagnosis. The CMP helps monitor hydration status and electrolyte disturbances, while the CBC may show elevated white blood cell count indicating inflammation or infection. Monitoring these parameters helps guide supportive care and identify complications.
Chronic Pancreatitis
In chronic cases, enzyme levels may be normal or mildly elevated, but pancreatic elastase-1 is typically low. This helps initiate enzyme replacement therapy and track its effectiveness. CMP values provide information on nutritional status and liver involvement.
Pancreatic Cancer
CA 19-9 is used for diagnostic support, treatment planning, and recurrence monitoring. Rising CA 19-9 after treatment may indicate disease progression. CEA and CA 125 can be used in combination for improved sensitivity in specific cases. CMP and CBC results guide systemic treatment readiness and monitor organ function during chemotherapy or surgery.
Pancreatic Exocrine Insufficiency
A low pancreatic elastase-1 level helps confirm enzyme insufficiency. Results guide dosing of pancreatic enzyme replacement and are monitored periodically to assess treatment adequacy and symptom resolution.
Gastrointestinal Malignancies
In elevated CEA or CA 125 cases, further imaging or endoscopic evaluations may be warranted. These markers are also used in known cancer patients to assess tumor burden, detect metastasis, and monitor response to therapy.
Metabolic Disorders
Lipid and glucose levels guide lifestyle interventions or pharmacologic treatment for diabetes, hyperlipidemia, or metabolic syndrome. This is particularly important in patients with pancreatitis, pancreatic cancer, or endocrine abnormalities.
Conclusion
The Pancreatic-Health & Cancer-Surveillance Comprehensive Panel is a powerful tool for evaluating the functional, enzymatic, and oncologic status of the pancreas while also assessing systemic and metabolic health. By integrating multiple types of laboratory data, this panel supports the early detection of pancreatic disease, assists in risk stratification, and provides critical information for personalized treatment planning and monitoring. Whether used for initial diagnosis, long-term surveillance, or post-treatment follow-up, this panel offers a comprehensive approach to managing complex pancreatic conditions.